Dekabank Deutsche Girozentrale Reduces $3M in Arcutis Biotherapeutics, Inc. ($ARQT)
Key Points
- Dekabank Deutsche Girozentrale changed its Arcutis Biotherapeutics, Inc. ($ARQT) stake by 100.0% last quarter, cutting to 0 shares.
- Wall Street's consensus rating on $ARQT is Strong Buy and an average price target of $34.62.
- $ARQT last traded around $24.59.
Dekabank Deutsche Girozentrale reduced its position in Arcutis Biotherapeutics, Inc. ($ARQT), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Arcutis Biotherapeutics, Inc. after selling 140,000 shares during the quarter.
Arcutis Biotherapeutics, Inc. ($ARQT) Stock
Arcutis Biotherapeutics, Inc. Earnings
Analysts Set New Price Targets
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.